APA (7th ed.) Citation

Butelet, A., Poulain, S., Jeanpierre, E., Srour, M., Nudel, M., Chauvet, P., . . . de Charette, M. (2022). Successful and safe response to ibrutinib alone in treating relapsed Waldenström macrogobulinemia and related acquired von Willebrand syndrome: An option to consider. Leukemia & Lymphoma, 63(13), 3100. https://doi.org/10.1080/10428194.2022.2113534

Chicago Style (17th ed.) Citation

Butelet, Alexandre, et al. "Successful and Safe Response to Ibrutinib Alone in Treating Relapsed Waldenström Macrogobulinemia and Related Acquired Von Willebrand Syndrome: An Option to Consider." Leukemia & Lymphoma 63, no. 13 (2022): 3100. https://doi.org/10.1080/10428194.2022.2113534.

MLA (9th ed.) Citation

Butelet, Alexandre, et al. "Successful and Safe Response to Ibrutinib Alone in Treating Relapsed Waldenström Macrogobulinemia and Related Acquired Von Willebrand Syndrome: An Option to Consider." Leukemia & Lymphoma, vol. 63, no. 13, 2022, p. 3100, https://doi.org/10.1080/10428194.2022.2113534.